Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 31, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Tuesday, shares in MannKind Corp. fluctuated between $5.34 and $5.58 before ending the session 4.12% lower at $5.35. The stock reported a trading volume of 3.25 million shares, below its three months average volume of 4.87 million shares. MannKind Corp.'s shares have declined 5.73% in the previous three trading sessions and 9.48% in the last three months. However, the stock has advanced 2.88% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $5.76 and $7.09, respectively. Moreover, shares of MannKind Corp. have a Relative Strength Index (RSI) of 50.04. Sign up and read the free notes on MNKD at:

http://get.Investor-Edge.com/pdf/?c=MannKind&d=31-Dec-2014&s=MNKD

Amgen Inc.'s stock lost 1.36%, to close the day at $160.63. The stock recorded a trading volume of 1.92 million shares, much below its three months average volume of 4.14 million shares. The stock oscillated between $160.18 and $162.73 during the session. Over the last three months and since the start of this year, Amgen Inc.'s shares have surged 14.36% and 40.80%, respectively. However, the stock has lost 0.02% in the previous three trading sessions. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $160.43 is above its 200-day moving average of $133.29. Additionally, Amgen Inc.'s stock traded at a PE ratio of 23.81 and has an RSI of 49.81. The complimentary notes on AMGN can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Amgen&d=31-Dec-2014&s=AMGN

On Tuesday, shares in Celldex Therapeutics Inc. recorded a trading volume of 0.89 million shares, lower than its three months average volume of 2.87 million shares. The stock ended the day at $18.18, which was 1.73% below its previous day's closing of $18.50, and registered an intraday range of $18.12 and $18.84.  Celldex Therapeutics Inc.'s shares have gained 6.44% in the previous three trading sessions and 40.28% in the last three months. However, the stock has declined 24.91% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $17.25 and $15.66, respectively. Furthermore, shares of Celldex Therapeutics Inc. have an RSI of 53.63. Register for free on Investor-Edge and access the latest research on CLDX at:

http://get.Investor-Edge.com/pdf/?c=Celldex%20Therapeutics&d=31-Dec-2014&s=CLDX

Juno Therapeutics Inc.'s stock declined 5.22%, to close Tuesday's session at $51.38, after oscillating between $50.76 and $53.90. The stock recorded a trading volume of 2.47 million shares during the session. Juno Therapeutics Inc.'s shares have surged 28.48% in the previous three trading sessions. Juno Therapeutics Inc. recently launched its IPO and debuted on NASDAQ Stock Market on December 19, 2014. The complete research on JUNO is available for free at:

http://get.Investor-Edge.com/pdf/?c=Juno%20Therapeutics&d=31-Dec-2014&s=JUNO

Ironwood Pharmaceuticals Inc.'s stock finished Tuesday's session 0.67% higher at $15.06. A total of 0.83 million shares were traded, which was below its three months average volume of 0.97 million shares. The stock moved between $14.81 and $15.32 during the session. Over the last one month and the previous three months, Ironwood Pharmaceuticals Inc.'s shares have surged 8.82% and 16.25%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 29.72%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $13.88 is greater than its 200-day moving average of $13.39. Ironwood Pharmaceuticals Inc.'s stock has an RSI of 58.12. Free in depth research on IRWD is available at:

http://get.Investor-Edge.com/pdf/?c=Ironwood%20Pharma&d=31-Dec-2014&s=IRWD

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.